TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05843253: Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Sponsor: Nationwide Children's Hospital · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$3,280,200

Rescue Site Savings

+$2,171,400

Unlock Full NCT05843253 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05843253 Rescue Dossier →